Viral Vector-Based Gene Therapy Drugs Market Report：the global market size is projected to grow from USD 4,576 million in 2024 to USD 16,868 million by 2030

Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.

According to the new market research report "Viral Vector-Based Gene Therapy Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030", published by QYResearch, the global Viral Vector-Based Gene Therapy Drugs market size is projected to grow from USD 4,576 million in 2024 to USD 16,868 million by 2030, at a CAGR of 24.3% during 2024-2030.

• Global Viral Vector-Based Gene Therapy Drugs MarketSize(US$ Million), 2019-2030

Source: QYResearch, "Viral Vector-Based Gene Therapy Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”

• Global Viral Vector-Based Gene Therapy Drugs Top10Players Ranking and Market Share (Ranking is based on the revenue of 2023, continually updated)

Source: QYResearch, "Viral Vector-Based Gene Therapy Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030”

According to QYResearch Top Players Research Center, the global key manufacturers of Viral Vector-Based Gene Therapy Drugs include Novartis, Bluebird Bio, Spark Therapeutics, uniQure, Orchard Therapeutics, GSK, GILD, JW Therapeutics, Sibiono, Latima, etc. In 2023, the global top 10 players had a share approximately 90% in terms of revenue.

Market Drivers:

1. Optimization and diversity of viral vectors

Viral vectors play a vital role in gene therapy, and the optimization of their performance is an important driving force for market development. In recent years, scientists have continuously modified and optimized viral vectors to improve their transduction efficiency, targeting specificity, stable expression of target genes and packaging capacity, while reducing immunogenicity and safety risks. For example, adeno-associated virus (AAV) and lentivirus (LV) are the two most commonly used viral vectors. They are widely used in gene therapy, and new serotypes and variants are constantly being discovered to meet different treatment needs.

2. Breakthroughs in gene editing technology

With the rapid development of gene editing technologies such as CRISPR-Cas9, single base editing (BE) and lead editing (PE), gene therapy has become more precise and efficient. These technologies can be combined with viral vectors to achieve more complex gene repair and replacement, providing new possibilities for the treatment of complex diseases such as single-gene genetic diseases and tumors. The advancement of gene editing technology has directly promoted the research and development and commercialization of gene therapy drugs based on viral vectors.

3. Improvement of production process

The production of viral vectors is one of the key links in the commercialization of gene therapy drugs. Improvements in production processes, including new viral packaging systems, increased cell culture density, and reduced empty shell rates, can significantly improve production efficiency and reduce production costs, thereby accelerating the launch of gene therapy drugs. In addition, standardization and scale-up of production processes are also important factors in market development, which helps to reduce drug prices and improve patient accessibility.

4. Success of clinical trials and support from regulatory policies

The successful cases of viral vector-based gene therapy drugs in clinical trials are an important driving force for market development. These successful cases not only verify the efficacy and safety of the drugs, but also enhance the confidence of investors and the public in gene therapy. At the same time, governments and relevant regulatory agencies are constantly optimizing and improving the approval policies for gene therapy drugs, providing a more favorable policy environment for the development and launch of drugs.

Market Restrictions:

1. High R&D and production costs:

The production of viral vectors involves complex bioprocesses and quality control processes, and has extremely high requirements for equipment and raw materials, resulting in a significant increase in production costs. Due to the long R&D cycle and high risk of gene therapy drugs, a large amount of capital investment and clinical trials are required, and these costs will eventually be reflected in the high pricing of the drugs. Compared with traditional drugs, the production scale of gene therapy drugs is small, and it is impossible to reduce unit costs through large-scale production, which further pushes up the cost of treatment.

2. Low patient base and high pricing strategy:

Gene therapy is mainly used to treat rare diseases, and the number of patients is relatively small, resulting in limited market capacity. In order to recover the high R&D and production costs, pharmaceutical companies have to adopt a high pricing strategy. This high pricing strategy makes gene therapy drugs unaffordable for most patients, limiting the expansion and popularization of the market.

3. Long preparation cycle caused by autologous process

Gene therapy drugs based on viral vectors usually need to be customized according to the individual differences of patients. This autologous process leads to a longer preparation cycle. For example, CAR-T therapy requires collecting T cells from the patient's body, genetically modifying them, and then infusing them back to the patient. The whole process takes several weeks. Patients who receive gene therapy are often in serious condition and have already failed conventional treatments. Too long a preparation cycle may cause the patient's condition to worsen while waiting for treatment, affecting the treatment effect.

About QYResearch

https://www.qyresearch.com

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 17 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

Contact Us:

If you have any queries regarding this report or if you would like further information, please contact us:

QY Research Inc.

Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States

E-mail: global@qyresearch.com

Tel: 001-626-842-1666(US)  0086-133 1872 9947(CN)

EN: https://www.qyresearch.com

JP: https://www.qyresearch.co.jp